Spontaneous overexpression of the long form of the Bcl-X protein in a highly resistant P388 leukaemia

British Journal of Cancer

Volumn 75, Issue 2, 1997, Pages 268-274

  Kuhl J S ^a,c   Krajewski, S ^b   Duran G E ^a   Reed, J C ^b   Sikic, B I ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BURNHAM INSTITUTE   (United States)

^c NONE   (Germany)

Author keywords

Apoptosis; bcl X; Doxorubicin; Multidrug resistance; Murine leukaemia

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ALKYLATING AGENT; AMSACRINE; ANTIMETABOLITE; APHIDICOLIN; CAMPTOTHECIN; CISPLATIN; CYCLOSPORIN; CYTARABINE; CYTOTOXIN; DNA FRAGMENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ENZYME INHIBITOR; ETOPOSIDE; GLUTATHIONE; GLYCOPROTEIN P; MITOXANTRONE; PROTEIN BAX; PROTEIN BCL 2; TOPOISOMERASE II INHIBITOR; UNCLASSIFIED DRUG; VINBLASTINE; VINCA ALKALOID;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG ACCUMULATION; ENZYME ACTIVITY; GLUTATHIONE METABOLISM; LEUKEMIA P 388; MOUSE; MULTIDRUG RESISTANCE; MULTIGENE FAMILY; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ULTRAVIOLET RADIATION;

EID: 0031015630     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.44     Document Type: Article

References (37)

1. Baas F, Jongsma APM, Broxterman HJ, Arceci RJ, Housman D, Scheffer GL, Riethorst A, van Groenigen M, Nieuwint AWM and Joenje H (1990) Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line. Cancer Res 50: 5392-5398
2. Bachui NR, Gordon SL and Gee MVA (1978) A general mechanism for microsomal activation of quinone anti-cancer agents to free radicals. Cancer Res 38: 1745-1750
3. Boise LH, Gonzalez GM, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez, G and Thompson CB (1993) Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608
4. Brophy NA, Marie JP, Rojas VA, Warnke RA, McFall PJ, Smith SD and Sikic BI (1994) Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: a critical evaluation by four techniques. Leukemia 8: 327-335
5. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie AH (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852
6. Datta R, Manome Y, Taneja N, Boise LH, Weichselbaum R, Thompson CB, Slapak CA and Kufe D (1995). Overexpression of Bcl-X-L by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Different 4: 363-70
7. Deffie AM, Bosman DJ and Goldenberg GJ (1989) Evidence for a mutant allele of the gene for DNA topoisomenise II in adriamycin-resistant P388 murine leukemia cells. Cancer Res 49: 6879-6882
8. Drake FH, Zimmerman JP, McCabe FL, Bartus HF, Per SR, Sullivan DM, Ross WE, Mattern MR, Johnson RK, Crooke ST and Mirabelli CK (1987) Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. J Biol Chem 262: 16739-16747
9. Endicott JA and Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137-171
10. Fanidi A, Harrington EA and Evan GI (1992) Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359: 554-556
11. Ganapathi R, Grabowski D, Ford J, Heiss C, Kerrigan D and Pommier Y (1989) Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resisiance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage. Cancer Commun 1: 217-224
12. Hanada M, Krajewski S, Tanaka S, Cazals-Hatem D, Spengler BA, Ross RA, Biedler JL and Reed JC (1993) Regulation of bcl-2 oncoprotein levels with differentiation of human neuroblastoma cells. Cancer Res 53: 4978-4986
13. Harker WG, Slate DL, Drake FH and Parr RL (1991) Miloxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 30: 9953-61
14. Hochhauser D and Harris AL (1993) The role of topoisomerase II alpha and beta in drug resistance. Cancer Treat Rev 19: 181-94
15. Kartner N, Evernden-Porelle D, Bradley G and Ling V (1985) Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316: 820-823
16. Krajewski S, Krajewska M, Shabaik A, Wang HG, Irie S, Fong L and Reed JC (1994) Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res 54: 5501-5507
17. Krajewski S, Zapata JM and Reed JC (1996) Detection of multiple antigens on Western blots. Anal Biochem 236: 221-228
18. Kramer RA, Zakher J and Kim G (1988) Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Science 241: 694-697
19. Kühl J-S, Durán GE, Chao NJ and Sikic BI (1993) Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow. Cancer Chemother Pharmacol 33: 10-16
20. Lau DHM, Lewis AD, Ehsan MN and Sikic BI (1991) Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res 51: 5181-5187
21. Ling YH, Priebe W and Perez-Soler R (1993) Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells. Cancer Res 53: 1845-1852
22. Lowe SW, Ruley HE, Jacks T and Housman DE (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967
23. Minchinton AI (1984) Measurements of glutathione and other thiols in cells and tissues: a simplified procedure based on the HPLC separation of monobromobimane derivatives of thiols. Int J Radiat Oncol Biol Phys 10: 1503-1506
24. Minn AJ, Rudin CM, Boise LH and Thompson CB (1995). Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 86: 1903-1910
25. Miyashita T and Reed JC (1993) Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81: 151-157
26. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Hoffman B, Lieberman D and Reed JC (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax in gene expression in vitro and in vivo. Oncogene 9: 1799-1805
27. Nakagawa K, Saijo N, Tsuchida S, Sakai M, Tsanokawa Y, Yokota J, Muramatsu M, Sato K, Terada M and Tew KD (1990) Glutathione-S-transferase π as a determinant of drug resistance in transfected cell lines. J Biol Chem 265: 4296-4301
28. Noonan KE and Roninson IB (1988) mRNA phenotyping by enzymatic amplification of randomly primed cDNA. Nucleic Acids Res 16: 10366
29. Oltvai ZN, Milliman CL, and Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 74: 609-619
30. Rabier MJ, Bruno NA and Slate DL (1991) Multifactorial resistance in LS174T human colon carcinoma cells selected with doxorubicin. Int J Cancer 49: 601-607
31. Reed JC (1994) Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6
32. Rowe TC, Chen GL, Hsiang Y-H and Liu LF (1986) DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res 46: 2021-2026
33. Sato T, Hanada M, Bodrug S, Irie S, Iwama N, Boise L, Thompson C, Fong L, Wang HG and Reed JC (1994) Interactions among members of the bcl-2 protein family analyzed with a yeast two-hybrid system. Proc Natl Acad Sci USA 91: 9238-9242
34. Sumantran VN, Ealovega MW, Nunez G, Clarke MF and Wicha MS (1995) Overexpression of Bcl-X-S sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 55: 2507-2510
35. Tewey KM, Rowe TC, Yang L, Halligan BD and Liu LF (1984) Adriamycin-induced DNA damage mediated by mammalian topoisomerase II. Science 226: 466-468
36. Thompson CB (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462
37. Tritton TR, Murphee SA and Sartorelli AC (1978) Adriamycin: a proposal on the specificity of drug action. Biochem Biophys Res Commun 84: 802-808